Compile Data Set for Download or QSAR
maximum 50k data
Found 10 Enz. Inhib. hit(s) with all data for entry = 7381
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192317(US9187459, 2)
Affinity DataIC50:  0.130nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192320(US9187459, 5)
Affinity DataIC50:  0.370nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192316(US9187459, 1)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192319(US9187459, 4)
Affinity DataIC50:  0.510nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192318(US9187459, 3)
Affinity DataIC50:  0.540nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192317(US9187459, 2)
Affinity DataIC50:  6nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192319(US9187459, 4)
Affinity DataIC50:  22nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192318(US9187459, 3)
Affinity DataIC50:  23nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192316(US9187459, 1)
Affinity DataIC50:  25nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-2(Homo sapiens (Human))
Newgen Therapeutics

US Patent
LigandPNGBDBM192320(US9187459, 5)
Affinity DataIC50:  91nMT: 2°CAssay Description:1) The compound is dissolved in DMSO to prepare a 10 mM solution, and was diluted to 100 micoM with water. When used for IC50 measurement, series dil...More data for this Ligand-Target Pair
In DepthDetails US Patent